Nasdaq GlobeNewswire

Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year

Del


U.S. Patient Utilization Grew 33%, Year Over Year

DANVERS, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today reported third quarter fiscal 2018 revenue of $154.0 million, an increase of 34% compared to revenue of $114.7 million for the same period of fiscal 2017.

Financial and operating highlights during the third quarter of fiscal 2018 include:

  • Worldwide revenue from Impella heart pumps totaled $148.0 million, an increase of 36% compared to revenue of $109.2 million during the same period in the prior year. U.S. revenue from Impella pumps grew 30% to $130.7 million and U.S. patient usage grew 33%.

  • Outside the U.S., revenue from Impella heart pumps totaled $17.3 million and was up 94% year over year, predominantly from Germany, which recorded $11.4 million, up 71%. Additionally, the Company recorded $1.1 million in revenue from Japan.

  • The installed base for Impella 2.5® heart pumps in the U.S. grew by an additional 10 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,181 sites. The installed customer base for Impella CP® heart pumps grew by 41 new U.S. hospitals, bringing the total number of Impella CP sites to 1,134. The installed customer base for Impella 5.0® heart pumps grew by 14 new U.S. hospitals, bringing the total number of Impella 5.0 sites to 498.

  • An additional 36 sites made initial purchases of Impella RP® heart pumps during the quarter, bringing the total number of sites to 222.

  • Third quarter fiscal 2018 GAAP net income was $13.4 million, or $0.29 per diluted share. Third quarter fiscal 2018 adjusted* net income before the recently enacted Tax Reform Act was $32.2 million, or $0.70 per diluted share, compared to $15.4 million or $0.34 per diluted share for the prior year period.  Third quarter fiscal 2018 adjusted* net income included income tax expense adjustments of approximately $18.8 million, or $0.41 per diluted share due primarily to the recently enacted Tax Reform Act and excess tax benefits on employee share-based compensation awards, which were not applicable in the prior year period.

  • Gross margin was 83.8% compared to 83.4% in the prior year.

  • Operating income was $44.8 million, or 29.1% operating margin, compared to $25.4 million, or 22.2% operating margin in the prior year.

  • The Company generated $56.7 million in cash from operating activities during the third quarter. Cash, cash equivalents and marketable securities totaled $350.7 million as of December 31, 2017, compared to $319.2 million at September 30, 2017. The Company currently has no debt.

  • In October 2017, the Company officially closed on the purchase of its Danvers, Massachusetts global headquarters for $16.5 million.

"It is an exciting time for the company as we collaborate with our customers to improve patient outcomes and the standard of care for circulatory support," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "The Field of Heart Recovery is growing and Abiomed is well positioned to capture the $5 billion U.S. market opportunity, while planting the seeds for future growth in global markets."

FISCAL YEAR 2018 OUTLOOK
The Company is increasing its fiscal year 2018 revenue guidance again to approximately $583 million, an increase of approximately 31% from the prior year. This compares to the Company's prior fiscal 2018 guidance of $565 million to $575 million and a 27% to 29% increase from the prior year. This guidance projects revenue to be approximately $164 million for the fourth quarter of fiscal 2018. The Company is increasing its fiscal year guidance for GAAP operating margin to approximately 26%.  This compares to the Company's prior fiscal 2018 guidance of 23% to 25%.

CONFERENCE CALL
The Company will host a conference call to discuss the results on Thursday, February 1, 2018, at 8:00 a.m. EST. Michael R. Minogue, Chairman, President and Chief Executive Officer and Robert L. Bowen, former Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. EST February 1, 2018 through 11:00 a.m. EST on February 8, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 2967997.

The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S. and in certain foreign countries. Impella 2.5, Impella 5.0, and Recovering hearts. Saving lives. are trademarks of Abiomed, Inc.
                       
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, future opportunities, expected regulatory approvals and fiscal year 2018 revenue and operating margin expectations. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

* USE OF NON-GAAP MEASURES
To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP financial measures: adjusted net income and adjusted net income per diluted share. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding the provisional income tax expense related to the Tax Reform Act; and the excess tax benefits associated with share-based compensation arrangements. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to its historical performance and liquidity. The Company believes these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company's business.

Adjusted net income and adjusted net income per diluted share. The Company defines adjusted net income as net income, net of the provisional income tax expense related to the Tax Reform Act and the excess tax benefits associated with share-based compensation arrangements. The Company defines adjusted net income per diluted share as adjusted net income divided by diluted shares used for GAAP purposes which are calculated as the weighted average outstanding shares plus dilutive potential shares outstanding during the period. See below for a reconciliation of adjusted net income and adjusted net income per diluted share to net income and net income per diluted share.

For further information please contact: 

Ingrid Goldberg,
Director, Investor Relations
978-646-1590
ir@abiomed.com

 

Abiomed, Inc. and Subsidiaries  
Consolidated Balance Sheets  
(Unaudited)  
(in thousands, except share data)  
           
    December 31, 2017   March 31, 2017  
ASSETS          
Current assets:          
Cash and cash equivalents   $   50,502     $   39,040    
Short-term marketable securities       250,751         190,908    
Accounts receivable, net        64,862         54,055    
Inventories        46,891         34,931    
Prepaid expenses and other current assets       9,192         8,024    
Total current assets       422,198         326,958    
Long-term marketable securities       49,485         47,143    
Property and equipment, net       107,977         87,777    
Goodwill       34,814         31,045    
In-process research and development       16,241         14,482    
Long-term deferred tax assets, net       75,201         34,723    
Other assets       13,686         8,286    
Total assets   $   719,602     $   550,414    
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable   $   21,991     $   20,620    
Accrued expenses       41,565         37,703    
Deferred revenue       11,797         10,495    
Current portion of capital lease obligation       -         799    
Total current liabilities       75,353         69,617    
Other long-term liabilities       466         3,251    
Contingent consideration       10,423         9,153    
Long-term deferred tax liabilities       878         783    
Capital lease obligation, net of current portion       -         15,539    
Total liabilities       87,120         98,343    
Commitments and contingencies          
Stockholders' equity:          
Class B Preferred Stock, $.01 par value       -         -    
Authorized - 1,000,000 shares; Issued and outstanding - none          
Common stock, $.01 par value       443         437    
Authorized - 100,000,000 shares; Issued - 45,995,445 shares at December 31, 2017 and 45,249,281 shares at March 31, 2017           
Outstanding - 44,271,905 shares at December 31, 2017 and 43,673,286 shares
at March 31, 2017
         
Additional paid in capital       605,697         565,962    
Retained earnings (accumulated deficit)       103,610         (46,959 )  
Treasury stock at cost - 1,723,540 shares at December 31, 2017 and 1,575,995 shares at March 31, 2017        (66,622 )       (46,763 )  
Accumulated other comprehensive loss       (10,646 )       (20,606 )  
Total stockholders' equity       632,482         452,071    
Total liabilities and stockholders' equity   $   719,602     $   550,414    
           

 

Abiomed, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share data)
                       
  Three Months Ended
December 31,
  Nine Months Ended
December 31,
  2017     2016     2017     2016  
Revenue:                      
Product revenue $   153,989     $   114,624     $   419,202     $   320,541  
Funded research and development     33         50         111         83  
      154,022         114,674         419,313         320,624  
Costs and expenses:                      
Cost of product revenue      24,994         18,987         68,483         51,366  
Research and development      17,706         16,349         54,027         50,061  
Selling, general and administrative      66,556         53,935         187,233         158,053  
      109,256         89,271         309,743         259,480  
Income from operations     44,766         25,403         109,570         61,144  
Other income:                      
Investment income, net     969         457         2,385         1,068  
Other expense, net     (81 )       (34 )       (25 )       (225 )
      888         423         2,360         843  
Income before income taxes     45,654         25,826         111,930         61,987  
Income tax provision     32,208         10,394         36,607         24,770  
Net income $   13,446     $   15,432     $   75,323     $   37,217  
                       
Basic net income per share $   0.30      $    0.36     $   1.71      $    0.86  
Basic weighted average shares outstanding     44,247         43,431         44,095         43,125  
                       
Diluted net income per share $   0.29      $    0.34     $   1.65      $    0.83  
Diluted weighted average shares outstanding     45,869         44,770         45,731         44,597  

 

Abiomed, Inc. and Subsidiaries
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(Unaudited)
(in thousands, except per share data)
                       
  Three Months Ended
December 31,
  Nine Months Ended
December 31,
  2017     2016   2017     2016
                       
GAAP net income $ 13,446     $ 15,432   $ 75,323     $ 37,217
GAAP net income includes the effect of the following items:                      
Effect of the Tax Reform Act on net deferred tax assets *   21,957       -     21,957       -
Excess tax benefits related to stock-based compensation awards **   (3,214 )     -     (24,490 )     -
    18,743       -     (2,533 )     -
Adjusted net income $ 32,189     $ 15,432   $ 72,790     $ 37,217
                       
                       
GAAP net income per share - diluted $ 0.29     $ 0.34   $ 1.65     $ 0.83
GAAP diluted net income per share includes the effect of the following items:                      
Effect of the Tax Reform Act on net deferred tax assets *   0.48       -     0.48       -
Excess tax benefits related to stock-based compensation awards **   (0.07 )     -     (0.54 )     -
  $ 0.41     $ -   $ (0.06 )   $ -
Adjusted net income per share - diluted $ 0.70     $ 0.34   $ 1.59     $ 0.83
                       
                       
Shares used in calculation of adjusted net income per diluted share   45,869       44,770     45,731       44,597
                       
                       
* On December 22, 2017, the Tax Cut and Jobs Act ("the Tax Reform Act") was enacted into law. This new tax law, among other items, reduces the U.S. federal statutory corporate income tax rate from 35% to 21% effective January 1, 2018. During the three and nine months ended December 31, 2017, the Company recorded a one-time income tax expense adjustment related to the revaluation of its deferred taxes due to a reduction of the U.S. federal statutory corporate income tax rate.
 
** In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required.

 

 

 

 

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

GlobeNewswire Test Release19.5.2018 07:00Pressemelding

LOS ANGELES, May 18, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539

BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23Pressemelding

PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55Pressemelding

TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules

Skybox Security and Exclusive Networks Announce New Partnership for Middle East Distribution of the Skybox Security Suite17.5.2018 18:41Pressemelding

The cybersecurity management platform ensures networks remain secure and compliant as organisations migrate to cloud and merge networks SAN JOSE, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, announced today a new partnership with Exclusive Networks for distribution of Skybox solutions in the Middle East, including the Gulf Cooperation Council (GCC) region and Egypt. Exclusive Networks will deploy and service the Skybox(TM) Security Suite, a broad security management platform that provides comprehensive attack surface visibility and enables unified vulnerability management and firewall/security policy management across an organization's entire network, including in physical, multi-cloud and OT environments. "Driven by government outlays (with oil, gas and defence industries leading the charge), Middle East organisations are looking for trusted security advisors who can navigate digital transformations and reduce risks - espec

Dermatological Symposium Tackles the Effects of Pollution on Skin17.5.2018 16:03Pressemelding

Researchers Present Compelling Evidence Showing the Effects of Pollution on Skin Health at Symposium Sponsored by Mary Kay Inc. DALLAS, May 17, 2018 (GLOBE NEWSWIRE) -- Mary Kay Inc. announced four keynote speakers for its symposium to be held during the prestigious International Investigative Dermatology (IID) Meeting on May 16 to 19, 2018 in Orlando, Florida. The IID meeting occurs once every 5 years, and brings together scientists from across the globe, highlighting the latest in cutting edge science in dermatology. The Mary Kay sponsored Symposium features four global experts including Dr. Liang Liu, Assistant Professor of Dermatology, Columbia University; Dr. Max Costa, Professor and Chairman of the department of Environmental Medicine, New York University School of Medicine; Dr. Jean Krutmann, Chair of Environmental Medicine at the Medical Faculty of Heinrich Heine University Düsseldorf and Director of the Leibniz Research Institute of Environmental Medicine in Dusseldorf, German

Talend Opens Nomination Period for Data Masters Awards17.5.2018 14:21Pressemelding

Annual Program Showcases Customers' Innovative Use of Cloud Technologies for Digital Transformation REDWOOD CITY, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, officially opened the submission period for its fourth annual Data Masters Awards. This program celebrates companies using Talend solutions in innovative, forward-thinking ways to put more data to work and enable more informed and impactful business decisions. Organizations interested in nominating a project can complete an official entry form here. Finalists will be chosen from Talend's more than 1,500 global customers representing large enterprises and private firms across all major industries including banking and insurance, consumer goods, healthcare, manufacturing and retail. Past award recipients include some of the world's best-known brands including: AIG, Air France/KLM, Beachbody, Citi, Credit Agricole Consumer Finance, GE Healthcare, HERMES

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom